3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
2
Phase 1/2
1
Status
Recruiting
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Sarcoma
1
NET
1
Endocrine
1
CNS
1
Conditions
Ovarian Neoplasms
8
Breast Neoplasms
8
Prostatic Neoplasms
5
Small Cell Lung Carcinoma
4
Stomach Neoplasms
3
Neoplasms
3
Lung Neoplasms
3
Fallopian Tube Neoplasms
3
Endometrial Neoplasms
3
Carcinoma, Non-Small-Cell Lung
3
Triple Negative Breast Neoplasms
2
Recurrence
2
Neuroendocrine Tumors
2
Neoplasm Metastasis
2
Glioma
2
Uterine Neoplasms
1
Urogenital Neoplasms
1
Squamous Cell Carcinoma of Head and Neck
1
Sarcoma, Synovial
1
Prostatic Neoplasms, Castration-Resistant
1
Prostatic Diseases
1
Pheochromocytoma
1
Peritoneal Neoplasms
1
Paraganglioma
1
Pancreatic Neoplasms
1
Osteosarcoma
1
Neuroblastoma
1
Neoplasms by Site
1
Metastatic Castration-Resistant Prostate Cancer
1
Meningioma
1
Interventions
Temozolomide
3
lutetium Lu 177 dotatate
2
Nivolumab
2
veliparib
1
picropodophyllin
1
olaparib
1
dostarlimab
1
dinutuximab
1
cemiplimab
1
bempegaldesleukin
1
abemaciclib
1
Radiotherapy
1
Proton Therapy
1
Irinotecan
1
Granulocyte-Macrophage Colony-Stimulating Factor
1
Etoposide
1
Ethanol
1
Carmustine
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Phase 1/2
×
Ependymoma
×
olaparib
×
Clear all
NCT06607692
2026-06-04
LUPARPED
Fundación de investigación HM
Phase 1/2
Recruiting
25 enrolled